TECENTRIQ
TECENTRIQ (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of various stages of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC). It is used as an adjuvant treatment following surgery, as a first-line therapy for metastatic disease, and for patients whose cancer has progressed during or after chemotherapy. The drug is administered either as a monotherapy or in combination with other chemotherapeutic agents and targeted therapies depending on the specific cancer type and genomic profile.
How TECENTRIQ Works
Atezolizumab is a monoclonal antibody that targets and binds to PD-L1, a protein expressed on tumor cells and immune cells that inhibits the body’s anti-tumor immune response. By blocking the interaction of PD-L1 with PD-1 and B7.1 receptors on T cells, the drug prevents the suppression of cytotoxic T-cell activity and proliferation. This blockade releases the inhibition of the
Details
- Status
- Prescription
- First Approved
- 2016-05-18
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
TECENTRIQ Approval History
What TECENTRIQ Treats
2 indicationsTECENTRIQ is approved for 2 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
TECENTRIQ Target & Pathway
ProTarget
An immune checkpoint receptor on T-cells that acts as an 'off switch' for immune responses. Cancer cells often exploit PD-1 by expressing its ligands (PD-L1/PD-L2), allowing tumors to evade immune detection. Blocking PD-1 releases this brake, enabling T-cells to recognize and attack cancer cells.
Pathway Context
PD-1 on T-cells binds to PD-L1/PD-L2 on tumor cells, suppressing immune attack
A protein expressed on tumor cells and immune cells that binds to PD-1 on T-cells, suppressing immune responses. Many cancers overexpress PD-L1 to avoid immune attack. Blocking PD-L1 prevents this immune suppression, allowing the body's T-cells to fight cancer.
A second ligand for PD-1, expressed on antigen-presenting cells and some tumors. PD-L2 binds PD-1 with higher affinity than PD-L1 but is less widely expressed. Drugs blocking PD-1 prevent both PD-L1 and PD-L2 interactions.
TECENTRIQ Competitors
Pro10 other drugs also target PD-1. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (PD-1). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to TECENTRIQ
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TECENTRIQ FDA Label Details
ProIndications & Usage
FDA Label (PDF)TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determin...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.